Faith-based hospitals receive Covid-19 pain relief drugs
Mr Nevin Bradford the Cipla chief executive officer poses with representatives of St Francis Hospital Nagalama, Mengo Hospital and Rubaga Hospital during the handover of hands over the Cipladon drugs in Kampala recently.
What you need to know:
- The Cipladon branded drug is a product of Cipla that helps in relieving Covid-19-related effects such as body aches and pains, which are some of the major symptoms of Covid-19
HIV and malaria drug manufacturer, Cipla Quality Chemical, has donated Covid-19 pain relief drugs to help patients battling Corona virus related symptoms.
The Cipladon branded drug is a product of Cipla that helps in relieving Covid-19-related effects such as body aches and pains, which are some of the major symptoms of Covid-19.
Speaking at the handover of the drugs, Mr Nevin Bradford, the Cipla chief executive officer, said the surge in Covid-19 cases has necessitated a number of medical innovations, necessitating Cipla, among others to launch an effervescent paracetamol tablet – Cipladon - which helps to relieve pain twice as fast as ordinary paracetamol tablets.
“We are cognizant of the fact that Covid-19 cases have increased tremendously in the past couple of months and it has impacted negatively on the health of Ugandans and the economy at large. That is why Cipla is trying to help by providing the necessary medication to Ugandans,” he said.
The drugs, which included a total of 5,000 doses of Cipladon, was mainly donated to faith-based medical facilities, among which included St Francis Hospital Nagalama, Mengo Hospital and Rubaga Hospital.
The donation, Mr Nevin said, is expected to continue with the target of reaching at least 25,000 patients.
Cipla is one of Uganda’s largest drug makers, specialising in HIV and malarial drugs, much of which is exported while the rest is consumed locally.
The pharmaceutical company operates a World Health Organization certified facility that manufactures a range of WHO pre-qualified medicines including ARVs for the treatment of HIV/AIDS and Artemisinin-based combination therapy for the treatment of malaria.
Mr Nevin noted that they have put focus on ensuring access to quality, affordable medication as part of a strategy and commitment that speaks to “caring for life”.
“We see a future where good health is expected, not for the few, but for the many. And we want to help make a difference during this pandemic in whichever way possible, starting by helping to relieve pain which can be a symptom of Covid-19,” he said.
